Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

This study tests two immunotherapy drugs — cetuximab and cemiplimab — given before surgery for head and neck squamous cell cancer (HNSCC) to see whether they can shrink the tumor and help the immune system fight cancer more effectively. **You may be eligible if:** - You are 18 years or older - You have been newly diagnosed with resectable (surgically removable) head and neck cancer (oral cavity, throat, larynx, or hypopharynx) - Your cancer is stage T1-2 N1-3 or T3-4 N0-3 - You are in good health (ECOG performance status 0 or 1) - You are planning to have surgery as standard treatment - You have adequate tumor tissue available for testing **You may NOT be eligible if:** - You have an active autoimmune disease requiring systemic treatment - You have a history of severe pneumonitis (lung inflammation) requiring steroids - You are allergic to cetuximab or have had a tick bite or red meat allergy - You have HIV, active hepatitis B or C infection - You have significant heart disease or severely reduced heart function - You are pregnant, breastfeeding, or cannot consent to the study Talk to your doctor to see if this trial is right for you.